Active, not recruitingPhase 2NCT02114229
Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors
Studying Atypical teratoid rhabdoid tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- St. Jude Children's Research Hospital
- Principal Investigator
- Amar Gajjar, MDSt. Jude Children's Research Hospital
- Intervention
- alisertib(drug)
- Enrollment
- 125 enrolled
- Eligibility
- 21 years · All sexes
- Timeline
- 2014 – 2027
Study locations (9)
- Lucille Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States
- Rady Children's Hospital, San Diego, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- UF Cancer Center at Orlando Health, Orlando, Florida, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Children's Hospital and Clinics of Minnesota, Minneapolis, Minnesota, United States
- St. Jude Children's Research Hospital, Memphis, Tennessee, United States
- Texas Children's Hospital, Houston, Texas, United States
Collaborators
Millennium Pharmaceuticals, Inc. · Takeda Pharmaceuticals U.S.A., Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02114229 on ClinicalTrials.govOther trials for Atypical teratoid rhabdoid tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06465199Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and SarcomasMilton S. Hershey Medical Center
- RECRUITINGEARLY PHASE1NCT07017816A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.Children's National Research Institute
- RECRUITINGPHASE2NCT06622941Study to ONO-4538 in Patients With Rhabdoid TumorOno Pharmaceutical Co. Ltd
- RECRUITINGPHASE1NCT06193759Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)Children's National Research Institute
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05407441Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def TumorsSusan Chi, MD
- RECRUITINGPHASE1NCT05835687Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS TumorsSt. Jude Children's Research Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05286801Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE2NCT06853080Feasibility of Using Bortezomib With or Without Chemotherapy in Patients With Atypical Teratoid/Rhabdoid TumorsTaipei Medical University